Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 5.97B |
| Revenue (ttm) | 947.36M |
| Net Income (ttm) | 392.47M |
| Shares Out | 127.23M |
| EPS (ttm) | 3.02 |
| PE Ratio | 15.54 |
| Forward PE | 10.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,217,071 |
| Open | 47.03 |
| Previous Close | 47.32 |
| Day's Range | 46.88 - 48.21 |
| 52-Week Range | 33.15 - 65.53 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 61.11 (+30.13%) |
| Earnings Date | Feb 18, 2025 |
About HALO
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ... [Read more]
Financial Performance
In 2023, Halozyme Therapeutics's revenue was $829.25 million, an increase of 25.62% compared to the previous year's $660.12 million. Earnings were $281.59 million, an increase of 39.31%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $61.11, which is an increase of 30.13% from the latest price.
News
Halozyme to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host invest...
Halozyme withdraws $2.1 bln buyout offer for Evotec
Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDA...
Halozyme CEO: Evotec Is Poised for Growth
Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology.
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
Halozyme says the combined company would have an estimated $2 billion in revenue in 2025.
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, sca...
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value ...
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/ ...
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong partnerships with J&J and Roche. The partnership model using ENHANZE tech m...
Halozyme Announces Record Earnings, Guidance
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Helen Torley - President, Chief Executive Officer Nicole LaBrosse - Chief F...
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million...
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate > $1...
Halozyme to Report Third Quarter 2024 Financial and Operating Results
SAN DIEGO , Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, Oc...
Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside
Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from "Overweight" to "Equal Weight," with a target price set at $62, indicating limited...
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
Four new targets nominated for total of six nominated targets, including FcRn (VYVGART® Hytrulo), for ENHANZE® drug delivery technology Halozyme to receive total upfront payment of $30 million for exc...
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. (“Halozyme”) (NASDAQ: HALO) on behalf of the company's shareholders. The investigation see...
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO , Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ...
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO , Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that...
Top 2 Health Care Stocks That May Plunge In August
As of Aug 26, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Final Trade: LULU, VIK, HALO, CCJ
The final trades of the day with CNBC's Leslie Picker and the Fast Money traders.
Halozyme Earnings, Guidance Point to Bullish Future
Strong revenue growth and a bright outlook have Halozyme Therapeutics, Inc. (HALO) shares rising.
Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Based on fundamental analysis, Halozyme Therapeutics, Inc. presents high returns on invested capital and returns on equity which will drive returns for investors. HALO is trading at a significant disc...
Halozyme Therapeutics, Inc. (HALO) Q2 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications ...